High Yield Income Fund Inc (HYI) investors sentiment decreased to 1.13 in 2018 Q4. It’s down -0.20, from 1.33 in 2018Q3. The ratio worsened, as 17 investment professionals increased and opened new stock positions, while 15 sold and trimmed stakes in High Yield Income Fund Inc. The investment professionals in our database reported: 6.53 million shares, down from 6.55 million shares in 2018Q3. Also, the number of investment professionals holding High Yield Income Fund Inc in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 12 Increased: 13 New Position: 4.
Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.44 EPS on April, 4.After having $-0.31 EPS previously, InflaRx N.V.’s analysts see 41.94% EPS growth. The stock decreased 0.24% or $0.09 during the last trading session, reaching $37.16. About 275,152 shares traded or 109.06% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since April 3, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $964.84 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” on February 14, 2019, also Globenewswire.com with their article: “InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management – GlobeNewswire” published on January 03, 2019, Seekingalpha.com published: “InflaRx down 14% – Seeking Alpha” on November 19, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – GlobeNewswire” published on December 19, 2018 as well as Globenewswire.com‘s news article titled: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” with publication date: February 06, 2019.
The stock increased 0.61% or $0.09 during the last trading session, reaching $14.8. About 103,890 shares traded. Western Asset High Yield Defined Opportunity Fund Inc. (HYI) has declined 0.14% since April 3, 2018 and is downtrending. It has underperformed by 4.51% the S&P500.
Rivernorth Capital Management Llc holds 0.8% of its portfolio in Western Asset High Yield Defined Opportunity Fund Inc. for 1.02 million shares. Private Management Group Inc owns 918,531 shares or 0.66% of their US portfolio. Moreover, Punch & Associates Investment Management Inc. has 0.31% invested in the company for 246,612 shares. The Georgia-based Capital Investment Advisors Llc has invested 0.26% in the stock. Saba Capital Management L.P., a New York-based fund reported 526,781 shares.
More notable recent Western Asset High Yield Defined Opportunity Fund Inc. (NYSE:HYI) news were published by: Businesswire.com which released: “Certain Closed-End Funds Advised by Legg Mason Partners Fund Advisor, LLC Announce Appointment of New Director and Retirements – Business Wire” on January 02, 2019, also Businesswire.com with their article: “Western Asset High Yield Defined Opportunity Fund Inc. Announces Results of Annual Meeting of Shareholders – Business Wire” published on October 01, 2018, Seekingalpha.com published: “2007-2018 DGI Vs. HYI Vs. Index Fund – Actual Performance Over 11 Years – Seeking Alpha” on July 27, 2018. More interesting news about Western Asset High Yield Defined Opportunity Fund Inc. (NYSE:HYI) were released by: Investorplace.com and their article: “4 Smart Retirement Buys for 7.2% Dividends and Big Gains – Investorplace.com” published on March 26, 2018 as well as Seekingalpha.com‘s news article titled: “Valuation Matters In Closed-End Funds – Seeking Alpha” with publication date: November 14, 2018.
Western Asset High Yield Defined Opportunity Fund Inc. is a closed ended fixed income mutual fund launched and managed by Legg Mason Partners Fund Advisor, LLC. The company has market cap of $. The fund is co-managed by Western Asset Management Company, Western Asset Management Company Pte. It currently has negative earnings. Ltd., Western Asset Management Company Ltd and Western Asset Management Company Limited.